Peter Anevski, Chief Executive Officer and Director of Progyny, Inc., filed a Form 4 on November 9, 2026, disclosing option exercises and common stock sales on November 5 and November 9, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Two exercise dates: Anevski exercised stock options on November 5, 2026 (3,400 shares) and November 9, 2026 (126,204 shares), both at a conversion price of $0.91 per share.
  • Shares sold on November 5: 3,400 shares at a weighted average price of $35.2276 and 8,539 shares at a weighted average price of $35.0906, with individual transaction prices ranging from $35.00 to $35.32.
  • Shares sold on November 9: 126,204 shares and 35,104 shares, both at a weighted average price of $35.7257, with individual transaction prices ranging from $35.00 to $35.99.
  • 10b5-1 plan: The 8,539-share and 35,104-share sales were made pursuant to a Rule 10b5-1 trading plan entered into on July 2, 2026.
  • Remaining beneficial ownership: Following all reported transactions, Anevski directly beneficially owned 762,468 shares of common stock.
  • Remaining options: After the exercises, 342,503 stock options (right to buy) with an exercise price of $0.91 and an expiration date of August 3, 2027, remained beneficially owned directly.

Anevski's Option Exercises and Stock Sales at Progyny: November 2026 Details

According to the filing, Peter Anevski, who serves as both Chief Executive Officer and Director of Progyny, Inc. (NASDAQ:PGNY), reported a series of transactions across two dates. On November 5, 2026, Anevski exercised options covering 3,400 shares of common stock at $0.91 per share, then sold those 3,400 shares at a weighted average price of $35.2276. On the same date, an additional 8,539 shares were sold at a weighted average price of $35.0906; those sales were made under a Rule 10b5-1 trading plan entered into on July 2, 2026. The filing notes that all per-share prices on November 5 ranged from $35.00 to $35.32 across multiple transactions.

On November 9, 2026, Anevski exercised options covering 126,204 shares at $0.91 per share, then sold those shares along with an additional 35,104 shares, all at a weighted average price of $35.7257. The filing indicates that the November 9 sale prices ranged from $35.00 to $35.99 per share across multiple transactions, and that the 35,104-share sale was also executed under the same July 2, 2026 Rule 10b5-1 plan. The filing states that all exercised options were "fully vested and exercisable" at the time of exercise, with an expiration date of August 3, 2027.

After all reported transactions, the filing shows Anevski directly beneficially owned 762,468 shares of common stock and 342,503 remaining stock options. The filing was signed by Mark Livingston as Attorney-in-Fact on November 9, 2026. The form indicates all transactions were made pursuant to a contract, instruction, or written plan satisfying the affirmative defense conditions of Rule 10b5-1(c).

What Was Disclosed

Progyny, Inc.'s CEO Peter Anevski disclosed option exercises totaling 129,604 shares at $0.91 per share and subsequent open-market sales across November 5 and November 9, 2026, leaving him with direct beneficial ownership of 762,468 shares of common stock.